completely agree - there is not much downside risk on this one Directors have put their hard earned money into this one and secondly their incentive options are well out of the money at the moment!
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game